Curve Therapeutics Announces Seed Investment from Advent Life Sciences

Southampton, UK, 27th June 2019. Curve Therapeutics (Curve) a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today announces a seed investment of £2.25 Mn from Advent Life Sciences, a leading trans-Atlantic venture investor focused on building innovative Life Sciences businesses in the UK, Europe and the USA.

Curve originated from world-leading Microcycle® research conducted by Professor Tavassoli’s group in the Department of Chemistry at the University of Southampton, UK. The company is  pioneering a game-changing, functional, drug discovery engine to generate higher quality functional hits and leads with the aim of discovering first-in-class therapeutics against challenging therapeutic targets.